Potential new treatments loom for acute leukemia

Thompson, Cheryl A.
November 2010
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1898
Academic Journal
The article reports that two pharmaceutical companies are confident that their lead drug development has the potential in acute myelogenous leukemia (AML) treatment. Cyclacel Pharmaceuticals Inc. says their oral nucleoside analogue, sapacitabine, causes single strand breaks in cancer cell DNA which interferes with the cancer cell mitosis. Meanwhile, Sunesis Pharmaceuticals Inc. mentions that their injectable quinolone derivative, vasaroxin, acts on the enzyme involved in DNA replication.


Related Articles

  • Imiquimod. Jobanputra, Kruti S.; Rajpal, Aruna V.; Nagpur, N. G. // Indian Journal of Dermatology, Venereology & Leprology;Nov/Dec2006, Vol. 72 Issue 6, p466 

    The article highlights the drug imiquimod, a heterocyclic imidazoquinoline amide that is an immune response modifying drug that has potent antiviral and antitumor activity. It also discusses the drug's pharmacokinetics, mechanism of action, indications, uses, contraindications, dosages and...

  • Cytarabine/daunorubicin/etoposide.  // Reactions Weekly;03/01/2013, Issue 1441, p13 

    The article presents a case study of a 16-month-old boy with acute myeloid leukaemia who developed tumour lysis syndrome (TLS) while receiving antineoplastics.

  • Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity. AGURA, EDWARD; COOPER, BARRY; HOLMES, HOUSTON; VANCE, ESTIL; BERRYMAN, ROBERT BRIAN; MAISEL, CHRISTOPHER; LI, SANDY; SARACINO, GIOVANNA; TADIC-OVCINA, MIRJANA; FAY, JOSEPH // Oncologist;Feb2011, Vol. 16 Issue 2, p197 

    Purpose. To determine the efficacy and safety of clofarabine and cytarabine (Ara-C) in adult patients with relapsed or refractory acute myeloid leukemia(AML)and in elderly patients with untreated AML and heart disease. Patients and Methods. Patients with relapsed/refractory AML and older...

  • Leukemia arsenal has new drugs.  // Oncology Nurse Advisor;January/February 2013, Vol. 4 Issue 1, p13 

    The article reports on the result of the clinical trials conducted by Jorge Cortes, deputy chair of the Department of Leukemia at The University of Texas, about the effectiveness of several leukemia drugs. These include the second-generation tyrosine kinase inhibitor (TKI) Bosulif, a synthetic...

  • Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Tschan-Plessl, A.; Halter, J.; Heim, D.; Medinger, M.; Passweg, J.; Gerull, S.; Halter, J P; Passweg, J R // Annals of Hematology;Nov2015, Vol. 94 Issue 11, p1899 

    The multikinase inhibitor sorafenib has shown a strong anti-leukemic effect in FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML); however, remission is often transient. To better understand the role of sorafenib, we performed a retrospective analysis of all patients who...

  • Bendamustine-Rituximab as First-line Treatment for NHL Patients Over the Age of 80 Years. Ershler, William B. // Clinical Oncology Alert;Oct2011, Vol. 27 Issue 10, p78 

    The author discusses a study by E. Weidmann and colleagues which concluded that the combination of bendamustine and rituximab is an effective first-line therapy for older patients with aggressive B-cell lymphomas. He comments on the low toxicity of bendamustine and its synergy with rituximab,...

  • Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Isakoff, S J; Wang, D; Campone, M; Calles, A; Leip, E; Turnbull, K; Bardy-Bouxin, N; Duvillié, L; Calvo, E // British Journal of Cancer;11/25/2014, Vol. 111 Issue 11, p2058 

    Background:This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/Abl tyrosine kinase inhibitor) plus capecitabine.Methods:Patients with locally advanced/metastatic breast, pancreatic, or colorectal cancers; cholangiocarcinoma; or...

  • Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Van Cutsem, E; Li, C-P; Nowara, E; Aprile, G; Moore, M; Federowicz, I; Van Laethem, J-L; Hsu, C; Tham, C K; Stemmer, S M; Lipp, R; Zeaiter, A; Fittipaldo, A; Csutor, Z; Klughammer, B; Meng, X; Ciuleanu, T // British Journal of Cancer;11/25/2014, Vol. 111 Issue 11, p2067 

    Background:This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose.Methods:After a 4-week run-in period (gemcitabine 1000 mg m−2 once weekly plus...

  • New drugs in acute myeloid leukemia. de Witte, Theo; Suciu, Stefan; Amadori, Sergio; Willemze, Roel // Drugs & Cell Therapies in Hematology;2014, Vol. 2 Issue 2, p86 

    Intensive chemotherapy regimens with or without stem cell transplantation are the current standard treatment in patients with acute myeloid leukemia (AML). The identification of new mutations in AML may provide the basis for a more targeted therapeutic approach. In one or several genetic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics